Anti-Human VEGF (Bevacizumab) – Fc Muted™
Anti-Human VEGF (Bevacizumab) – Fc Muted™
Product No.: LT405
Product No.LT405 Clone A4.6.1 Target VEGF Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Vascular Endothelial Growth Factor; VEGF-A; VEGFA; Vascular Permeability Factor; VPF Isotype Human IgG1κ Applications B , ELISA , FC , IP , N , WB |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Muted Immunogen Recombinant human VEGF. Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥95% monomer by analytical SEC Formulation This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping 2-8°C Wet Ice RRIDAB_2893958 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Adalimumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. WB ELISA Additional Applications Reported In Literature ? B N IP Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. Bevacizumab recognizes both native and reduced human VEGF (isoform 165). This product is for research use only. Background Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.1 Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects. Antigen Distribution VEGF is widely expressed in the thyroid, prostate, and various other tissues. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Bevacizumab biosimilars are used as calibration standards or reference controls in pharmacokinetic (PK) bridging ELISA assays to quantitatively measure drug concentrations in serum samples. These biosimilars serve as standardized materials to establish calibration curves or to validate assay performance, ensuring the accurate measurement of Bevacizumab—or biosimilar—levels during PK bridging studies. Key roles and procedures:
Summary of process in a typical PK ELISA:
Research-grade Bevacizumab biosimilars are thus essential to PK bridging ELISA workflows, functioning as calibration standards and reference controls to ensure accurate, reproducible, and regulatory-compliant quantification of drug concentrations in serum during biosimilar development and comparative PK studies. The primary in vivo models for administering research-grade anti-VEGF antibodies to study tumor growth inhibition and characterize tumor-infiltrating lymphocytes (TILs) are syngeneic mouse models and, to a lesser extent, humanized mouse models. Syngeneic Models:
Humanized Models:
Xenograft Models:
Summary Table: Model Comparison for Anti-VEGF/TIL Studies
Conclusion: For immunological characterization of TILs in the context of anti-VEGF therapy, syngeneic mouse models remain the gold standard due to their robust immunocompetence and suitability for in vivo antibody administration. Humanized models are an alternative when human immune–tumor interactions are required, albeit with practical and technical limitations. Researchers are exploring the use of bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, in combination with immune checkpoint inhibitors to enhance synergistic effects in treating cancers. While specific studies on bevacizumab biosimilars combined with checkpoint inhibitors like anti-CTLA-4 or anti-LAG-3 biosimilars are limited, the concept revolves around leveraging the immunomodulatory effects of VEGF pathway inhibition to complement the action of checkpoint inhibitors. Combining Bevacizumab with Checkpoint Inhibitors
Challenges and Future Directions
ConclusionWhile the specific use of bevacizumab biosimilars in combination with anti-CTLA-4 or anti-LAG-3 biosimilars is not yet well-documented, researchers are actively exploring combinations of anti-VEGF agents with checkpoint inhibitors to enhance cancer treatment outcomes. Future studies will need to focus on these specific combinations to fully understand their potential synergistic effects. In the context of immunogenicity testing, a Bevacizumab biosimilar can be used as either a capture or detection reagent in a bridging ADA ELISA to monitor a patient's immune response against the therapeutic drug. Here's how it could be utilized: Bridging ADA ELISA ProtocolThe bridging ADA ELISA is a versatile assay format used to detect anti-drug antibodies (ADAs) against therapeutic drugs like Bevacizumab. This approach typically involves:
Use of Bevacizumab BiosimilarUsing a Bevacizumab biosimilar as a capture or detection reagent in a bridging ADA ELISA offers several advantages:
However, challenges such as interference from endogenous VEGF and the need for innovative dissociation methods to remove tightly bound drug components must be addressed to optimize the assay's performance. Customization and OptimizationEach laboratory should customize and implement the bridging ELISA protocol according to their specific requirements, including the selection of high-quality reagents and optimal assay conditions to ensure accurate and reliable results. By using a Bevacizumab biosimilar in this context, researchers can effectively monitor a patient's immune response to Bevacizumab and assess the drug's immunogenicity, which is critical for evaluating treatment efficacy and safety. References & Citations1. Pazdur, R. et al. (2018) Clin Cancer Res. 24(18):4365-70. Technical ProtocolsCertificate of Analysis |
Formats Available
